Skip to main content
. 2005 Nov 29;94(1):30–35. doi: 10.1038/sj.bjc.6602892

Figure 2.

Figure 2

Estimated proportion of patients prescribing AI at the time of the survey and in 2–3 years time based on the question: What proportion of your ER+early breast cancer patients would you prescribe aromatase inhibitors to either instead of tamoxifen or after an initial course of tamoxifen? In all, 35 specialists gave no response for 2–3 years time.